[go: up one dir, main page]

ATE297208T1 - Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit - Google Patents

Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit

Info

Publication number
ATE297208T1
ATE297208T1 AT98945805T AT98945805T ATE297208T1 AT E297208 T1 ATE297208 T1 AT E297208T1 AT 98945805 T AT98945805 T AT 98945805T AT 98945805 T AT98945805 T AT 98945805T AT E297208 T1 ATE297208 T1 AT E297208T1
Authority
AT
Austria
Prior art keywords
parkinson
disease
release tablet
extended
treatment
Prior art date
Application number
AT98945805T
Other languages
English (en)
Inventor
Tzu-Chi Robert Ju
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE297208T1 publication Critical patent/ATE297208T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98945805T 1997-09-30 1998-09-03 Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit ATE297208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (1)

Publication Number Publication Date
ATE297208T1 true ATE297208T1 (de) 2005-06-15

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945805T ATE297208T1 (de) 1997-09-30 1998-09-03 Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit

Country Status (22)

Country Link
US (2) US6197339B1 (de)
EP (1) EP1017391B1 (de)
JP (1) JP2001517701A (de)
KR (1) KR100516095B1 (de)
CN (1) CN1195518C (de)
AT (1) ATE297208T1 (de)
AU (1) AU742941B2 (de)
BR (1) BR9812687A (de)
CA (1) CA2301869A1 (de)
DE (1) DE69830503T2 (de)
DK (1) DK1017391T3 (de)
ES (1) ES2242296T3 (de)
FI (1) FI20000720A7 (de)
HU (1) HUP0004586A2 (de)
NO (1) NO320303B1 (de)
NZ (1) NZ504221A (de)
PL (1) PL191125B1 (de)
PT (1) PT1017391E (de)
RU (1) RU2205007C2 (de)
SI (1) SI1017391T1 (de)
SK (1) SK3612000A3 (de)
WO (1) WO1999016442A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144670A0 (en) 1999-02-05 2002-05-23 Upjohn Co Process to prepare (5r) - (methylamino) -5,6-dihydro-4h-imidazo [4,5,1-ij]-quinolin-2 (1h) -one
KR20100036398A (ko) 1999-03-31 2010-04-07 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
EP2305253A1 (de) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Verwendung von Pramipexol zur Behandlung amyotropher Lateralsklerose
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PL223471B1 (pl) * 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
BR0314526A (pt) * 2002-10-04 2005-07-26 Pharmacia Corp Composições farmacêuticas para o tratamento do mal de parkinson
AU2003277296A1 (en) * 2002-10-04 2004-05-04 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004037971A2 (en) * 2002-10-25 2004-05-06 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
KR101052436B1 (ko) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
JP2009526021A (ja) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 放出を加減した製剤
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
HK1200850A1 (en) 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
LT3838271T (lt) 2013-07-12 2025-11-10 Padidėjusio eozinofilų ir (arba) bazofilų kiekio gydymas
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
KR20240055886A (ko) * 2021-09-17 2024-04-29 하이노바 파마슈티컬스 인코포레이티드 퀴놀린계 화합물의 서방성 정제 및 그 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
WO1999016442A3 (en) 1999-06-17
PL191125B1 (pl) 2006-03-31
EP1017391B1 (de) 2005-06-08
HK1030163A1 (en) 2001-04-27
KR20010030776A (ko) 2001-04-16
SI1017391T1 (sl) 2005-12-31
CA2301869A1 (en) 1999-04-08
PT1017391E (pt) 2005-09-30
NO320303B1 (no) 2005-11-21
AU742941B2 (en) 2002-01-17
FI20000720L (fi) 2000-03-29
DK1017391T3 (da) 2005-08-22
JP2001517701A (ja) 2001-10-09
AU9296498A (en) 1999-04-23
NO20001624D0 (no) 2000-03-29
CN1268890A (zh) 2000-10-04
WO1999016442A2 (en) 1999-04-08
RU2205007C2 (ru) 2003-05-27
BR9812687A (pt) 2000-08-22
US20010053386A1 (en) 2001-12-20
NZ504221A (en) 2004-11-26
CN1195518C (zh) 2005-04-06
ES2242296T3 (es) 2005-11-01
EP1017391A2 (de) 2000-07-12
FI20000720A7 (fi) 2000-03-29
HUP0004586A2 (hu) 2001-06-28
PL339946A1 (en) 2001-01-15
DE69830503D1 (de) 2005-07-14
KR100516095B1 (ko) 2005-09-23
DE69830503T2 (de) 2006-03-16
NO20001624L (no) 2000-03-29
US6197339B1 (en) 2001-03-06
SK3612000A3 (en) 2000-09-12

Similar Documents

Publication Publication Date Title
ATE297208T1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
EE9900465A (et) Uued ühendid
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
ES2091689T3 (es) Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
DK0793498T3 (da) Bicykliske heterocykliske forbindelser til behandling af impotens
HUP0004350A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
IS5082A (is) Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja
NO20013645D0 (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjonen av perifere benzodiazepinreseptorer
BG105714A (en) Use of imidazolo[1,5-a]-pyrido[3,2-e]pyrazinons as medicaments
AR018925A1 (es) Derivados de triazolo-piridazina como ligandos para receptores de gaba, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento.
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
TR199801069T2 (xx) Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen t�revleri ve bunlar�n terap�tik kullan�m�
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017391

Country of ref document: EP

REN Ceased due to non-payment of the annual fee